Skip to Main content Skip to Navigation
Journal articles

Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma

Abstract : The therapeutic landscape of relapsed multiple myeloma (MM) is constantly evolving. To date, a large proportion of patients present with lenalidomide refractory disease at the time of first or second relapse. In this context, few efficient options are currently available. Carfilzomib and daratumumab are approved in the relapse setting. Recently, Phase Ib and Phase III trials evaluated the triplet drug combination daratumumab–carfilzomib–dexamethasone in the relapse setting and demonstrated strong clinical efficacy, especially in lenalidomide refractory patients. Based on these results, this combination has been approved by the US FDA for relapsed MM patients. The present review discusses the safety and efficacy of daratumumab–carfilzomib–dexamethasone in MM.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03496299
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Monday, December 20, 2021 - 2:11:39 PM
Last modification on : Wednesday, April 27, 2022 - 4:21:48 AM

Identifiers

Citation

Cyrille Touzeau, Chloé Antier, Philippe Moreau. Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma. Future Oncology, Future Medicine, 2021, 17 (9), pp.993-998. ⟨10.2217/fon-2020-0907⟩. ⟨inserm-03496299⟩

Share

Metrics

Record views

13